glp-1 therapy protein intake optimization research Dietary patterns and nutritional adequacy among adults with overweight or obesity treated with or dual GIP/GLP-1 receptor agonists- preliminary study | Journal of Translational Medicine Protein Intake on GLP-1 Medications:

Comprehensive nutritional and dietary intervention for autism spectrum disorder-a randomized, controlled 12-month trial

Continuing the medication is not a failure, its evidence-based maintenance

GLP-1RA or dual GIP/GLP-1RA added to basal insulin compared to basal insulin titrated with a rigorous intention-to-treat approach is moderately effective in preventing further increase in daily basal insulin dose from achieving treat-to-target glycemic goals ( daily insulin dose, SMD -0.49, 95% CI -0.71

Liraglutide (Saxenda/Victoza, Novo Nordisk) was the most common GLP-1 in the review and was included as the lone therapy in 16 studies and in combination with dulaglutide (Trulicity, Eli Lilly) in two studies